We believe that we can and will beat cancer. There are things that we can all do every day to help make this happen. Every year in NSW alone, more than 37,500 new cases of cancer are expected to be diagnosed, and the impact on families, carers and communities is significant. Our goal is to reduce deaths from cancer by 50% over the next 20 years.
Together with our volunteers, supporters, stakeholders and staff, we are committed to reducing the impact of cancer on individuals and the community, and to lessening the burden for people affected by cancer.
We are the only organisation that works across every area of every cancer:
We are there not only for those touched by cancer today, but to prevent and manage cancer into the future.
We are a member of Cancer Council Australia, together with Cancer Councils from every state and territory across Australia. Cancer Council NSW is an independent charity and 97% community funded. Our unique combination of local program delivery, community engagement and national influence enables everyone who cares about cancer to make the biggest possible difference.
Our Mission
To lead, empower and mobilise the community to beat cancer.
Our Values
Our values influence the work that we do, and the way we work with our colleagues and with our community.
Innovation Seek and embrace the best
Responsibility Be accountable for our results and resources
Courage Speak out and step up
Collaboration Work together to achieve our goals
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close